Patent · US Active

Mutated immunoglobulin-binding polypeptides

US12037359B2 · kind B2 · utility

0Cited by

95References

29Claims

0Family size

Assignee

Cytiva BioProcess R&D AB · SE

Inventors

Gustav Rodrigo · Uppsala, SE
Tomas Bjorkman · Uppsala, SE
Mats Ander · Uppsala, SE

Key dates

Filing date	Dec 8, 2020
Grant date	Jul 16, 2024
Priority date	—
Expiry date	Jun 9, 2042

Classification

Technology area (CPC B)Performing Operations; Transporting
CPC primaryB01J2220/52
WIPO fieldChemical engineering
WIPO sectorChemistry

Abstract

An Fc-binding polypeptide of improved alkali stability, comprising a mutant of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 22, SEQ ID NO: 51 or SEQ ID NO: 52, wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO: 4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.